109 related articles for article (PubMed ID: 15911234)
1. Docetaxel administration schedule: from fever to tears? A review of randomised studies.
Engels FK; Verweij J
Eur J Cancer; 2005 May; 41(8):1117-26. PubMed ID: 15911234
[TBL] [Abstract][Full Text] [Related]
2. Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials.
Bria E; Cuppone F; Ciccarese M; Nisticò C; Facciolo F; Milella M; Izzo F; Terzoli E; Cognetti F; Giannarelli D
Cancer Treat Rev; 2006 Dec; 32(8):583-7. PubMed ID: 16919884
[TBL] [Abstract][Full Text] [Related]
3. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.
Schuette W; Nagel S; Blankenburg T; Lautenschlaeger C; Hans K; Schmidt EW; Dittrich I; Schweisfurth H; von Weikersthal LF; Raghavachar A; Reissig A; Serke M
J Clin Oncol; 2005 Nov; 23(33):8389-95. PubMed ID: 16293869
[TBL] [Abstract][Full Text] [Related]
4. Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer.
Lai CL; Tsai CM; Chiu CH; Wang GS; Su WJ; Chen YM; Perng RP
Jpn J Clin Oncol; 2005 Dec; 35(12):700-6. PubMed ID: 16303792
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer.
Ford HE; Yap YS; Miles DW; Makris A; Hall M; Miller L; Harries M; Smith IE; Johnston SR
Cancer Chemother Pharmacol; 2006 Dec; 58(6):809-15. PubMed ID: 16528527
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel administered every two weeks as second-line chemotherapy for advanced non-small cell lung cancer: a phase II study.
De Petris L; Migliorino MR; Ceribelli A; Martelli O; Di Molfetta M; Mancuso A; De Santis S; Di Salvia R; De Marinis F
Anticancer Res; 2005; 25(6C):4713-7. PubMed ID: 16334165
[TBL] [Abstract][Full Text] [Related]
7. Weekly docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer: a phase I/II study with 5 years' follow-up.
Brunsvig PF; Hatlevoll R; Berg R; Lauvvang G; Owre K; Wang M; Aamdal S
Lung Cancer; 2005 Oct; 50(1):97-105. PubMed ID: 16005105
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel (Taxotere) administered in weekly schedules.
Greco FA
Semin Oncol; 1999 Jun; 26(3 Suppl 11):28-31. PubMed ID: 10458208
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer.
Miller VA; Kris MG
Semin Oncol; 2000 Apr; 27(2 Suppl 3):3-10. PubMed ID: 10810932
[TBL] [Abstract][Full Text] [Related]
10. Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer.
Tibaldi C; Bernardini I; Chella A; Russo F; Vasile E; Malventi M; Falcone A
Clin Lung Cancer; 2006 May; 7(6):401-5. PubMed ID: 16800966
[TBL] [Abstract][Full Text] [Related]
11. Is weekly docetaxel an active and gentle chemotherapy in the treatment of metastatic breast cancer?
Maisano R; Mare M; Zavettieri M; Caristi N; Mesiti M; Scisca C; La Torre F
Anticancer Res; 2003; 23(2C):1923-6. PubMed ID: 12820480
[TBL] [Abstract][Full Text] [Related]
12. Practical aspects of weekly docetaxel administration schedules.
Hainsworth JD
Oncologist; 2004; 9(5):538-45. PubMed ID: 15477638
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel: a tubulin-stabilizing agent approved for the management of several solid tumors.
Ramaswamy B; Puhalla S
Drugs Today (Barc); 2006 Apr; 42(4):265-79. PubMed ID: 16703123
[TBL] [Abstract][Full Text] [Related]
14. Low-dose weekly docetaxel is as tolerable as pemetrexed in previously treated advanced non-small-cell lung cancer.
Chung FT; Lee KY; Fang YF; Shieh MH; Lin SM; Yu CT; Lo YL; Lin TY; Kuo CH; Feng PH; Ni YL; Kuo HP
Chemotherapy; 2011; 57(2):147-55. PubMed ID: 21454972
[TBL] [Abstract][Full Text] [Related]
15. Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients.
Takigawa N; Segawa Y; Kishino D; Fujiwara K; Tokuda Y; Seki N; Shinkai T; Watanabe Y; Hiraki S; Kozuki T; Gemba K; Tabata M; Kiura K; Ueoka H; Tanimoto M
Cancer Chemother Pharmacol; 2004 Sep; 54(3):230-6. PubMed ID: 15127232
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of docetaxel administered by bi-weekly infusion to patients with metastatic breast cancer.
Shin E; Ishitobi M; Hiraoia M; Kazumasa F; Hideyuki M; Nishisho I; Toshiro S; Yasunori H; Tosimasa T
Anticancer Res; 2000; 20(6C):4721-6. PubMed ID: 11205207
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trials.
Fossella FV
Semin Oncol; 1999 Oct; 26(5 Suppl 16):17-23; discussion 41-2. PubMed ID: 10585004
[TBL] [Abstract][Full Text] [Related]
18. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
[TBL] [Abstract][Full Text] [Related]
19. Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.
Engels FK; Sparreboom A; Mathot RA; Verweij J
Br J Cancer; 2005 Jul; 93(2):173-7. PubMed ID: 16012521
[TBL] [Abstract][Full Text] [Related]
20. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer.
Di Maio M; Perrone F; Chiodini P; Gallo C; Camps C; Schuette W; Quoix E; Tsai CM; Gridelli C
J Clin Oncol; 2007 Apr; 25(11):1377-82. PubMed ID: 17416857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
